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Objective: To explore the anti-proliferative activity of puriﬁed L-asparaginase from
Aspergillus oryzae CCT 3940 (A. oryzae).
Methods: L-asparaginase was produced by submerged fermentation and puriﬁed to
electrophoresis homogeneity by ionic exchanged chromatography in a fast protein liquid
chromatographic system. The puriﬁed enzyme was characterized and used for the anti-
proliferative assay against nine tumor cell lines and one non-tumor cell line.
Results: The free glutaminase L-asparaginase was puriﬁed 28.6 fold. L-asparaginase
showed high stability under physiological condition, remaining stable in the pH range
7.0–8.0 after 1 h incubation at temperature range 30–45 C. The Km and Vmax values of
puriﬁed L-asparaginase were estimated as 0.66 mmol/L and 313 IU/mL, respectively. The
puriﬁed enzyme could inhibit the growth of a broad range of human tumor cell lines at the
concentrations studied. Also, the enzyme from A. oryzae CCT 3940 could inhibit tumor
growth of leukemia cell line (K562) with a total growth inhibition value of (3.2 ± 2.5) IU/
mL and did not inhibit the non-carcinogenic human cell line growth at the concentrations
studied.
Conclusions: The sensitivity of the cells lines to puriﬁed L-asparaginase from A. oryzae
CCT 3940 appeared to be concentration dependent affording a more signiﬁcant decrease
in cell growth than that observed for the commercial L-asparaginase from Escherichia
coli. The L-asparaginase from A. oryzae CCT 3940 has a high potential for pharmaceu-
tical exploitation in the treatment of leukemia.1. Introduction
L-asparaginase is an important chemotherapeutic agent used
to treat a variety of diseases of the lymphatic system, and
lymphomas such as acute lymphoblastic leukemia [1]. The
enzyme has also been applied in the treatment of Hodgkin's
disease, acute myelocytic leukemia, acute myelomonocyticleukemia, chronic lymphoblastic leukemia, lymphosarcoma,
reticulosarcoma and melanosarcoma [2]. In the normal animal
cell, L-asparagine is not an essential amino acid for the
maintenance of cell viability since cell supplies the absence of
amino acid through the action of asparagine synthetase [3].
Asparagine synthetase is an intracellular enzyme responsible
for the de novo synthesis of asparagine. However, the
neoplastic cells are not able to induce the synthesis of
asparagine synthetase, and they are dependent on the
extracellular level of L-asparagine to protein synthesis. As L-
asparagine is withdrawn from plasma by L-asparaginase, the
resulting small concentration of this amino acid leads to
disrupting protein synthesis and consequently cell growth
inhibition in neoplastic cells [4]. Thus, L-asparaginase is used
as an antitumor agent injecting the enzyme intravenously for
lowering the concentration of L-asparagine, selectively
affecting neoplastic cells dependent on this amino acid [5].article under the CC BY-NC-ND license (http://
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against acute lymphoblastic leukemia, the native L-asparaginase
from Escherichia coli (E. coli) (Elspar®), its pegylated form
(Oncaspar®) and L-asparaginase from Erwinia chrysanthemi
(Erwinase®). The ability to substantially reduce the plasma levels
of L-asparagine and keep it low for an extended period is the main
feature responsible for the anti-neoplastic activity of L-asparaginase
[6]. Despite signiﬁcant progress in developing formulations of L-
asparaginase, they are not free of adverse effects. There are some
limiting factors for the use of L-asparaginase in chemotherapy,
such as low catalytic activity that requires the use of high
concentrations of each application [1], toxic effects, such as
hyperglycemia, decreased serum albumin, lipoproteins, and
ﬁbrinogen, increased fat in the liver and some mild brain
dysfunction [7]. The primary limiting factor is the development of
hypersensitivity to the processing, which occurs in 50% of
treated patients during the therapy with L-asparaginase from
E. coli [8]. Even the pegylated form of L-asparaginase from
E. coli also shows hypersensitivity reactions, thus requiring a
shift to another form of L-asparaginase [9]. The hypersensitivity is
associated with the production of antibodies, which may reduce
the activity of L-asparaginase, causing the increase of the amino
acid asparagine and possible development of drug resistance [10].
L-asparaginase also contributes to the activity of glutaminase,
rapidly reducing the circulating glutamine concentrations in the
plasma of patients, since this is converted into glutamic acid and
ammonia [11]. The toxicity of asparaginase is partly attributable
to the glutaminase activity of these proteins, and the cytotoxicity
of L-asparaginase is determined primarily by its glutaminase
activity [12]. Therefore, the activity of glutaminase in therapeutic
preparations of L-asparaginases has been implicated in the cause
of some side effects [1].
The extensive research is, therefore, going on worldwide
with eukaryotic L-asparaginases looking for less adverse effects
than those observed for bacterial enzymes [2,13]. However, few
reports are available for the extracellular secretion of L-
asparaginases by fungi, their characterization, and puriﬁcation.
The search for an L-asparaginase producing organism with no
glutaminase activity, relevant biochemical characteristics, and
high puriﬁcation yields is a continuous exercise.
This paper deals with the puriﬁcation and biochemical
characterization of a glutaminase-free L-asparaginase from
Aspergillus oryzae CCT 3940 (A. oryzae) and its anti-
proliferative activity against human cancer cell lines in com-
parison with L-asparaginase from E. coli and the cytostatic
antibiotic doxorubicin.
2. Materials and methods
2.1. Chemicals
Commercial L-asparaginase from E. coli was purchased from
Megazyme (Wicklow, Ireland). Nessler's reagent was purchased
from Merck® (Darmstadt, Germany); L-asparagine and L-gluta-
mine were purchased from Sigma–Aldrich® (Missouri, USA).
Other reagents were obtained from Synth® (São Paulo, Brazil).
2.2. Microorganisms
The ﬁlamentous fungi A. oryzae CCT 3940 was previously
selected as an L-asparaginase producer strain from the CultureCollection of Andre´ Tosello Foundation, Campinas, SP, Brazil.
The strain was periodically subcultured and maintained on potato
dextrose agar slants.
2.3. L-asparaginase production
Conidial suspension was prepared from freshly raised seven-
day-old culture on potato dextrose agar medium with a 5 mL of
sterile 0.3% Tween 80 solution. The suspension was aseptically
transferred to 250 mL Erlenmeyer ﬂask containing 50 mL of
modiﬁed and previously optimized Czapek Dox medium [14]
composed of 5.0 g glucose, 10.0 g proline, 2.0 g L-asparagine,
5 g yeast extract, 1.52 g KH2PO4, 0.52 g KCl, 0.52 g
MgSO4$7H2O, 0.01 g CuNO3$3H2O, 0.01 g ZnSO4$7H2O
and 0.01 g of FeSO4$7H2O per liter and initial pH adjusted to
7.0. The ﬂasks were incubated at 30 C and 150 r/min for
72 h. The fungi cultures were ﬁltered through a paper ﬁlter,
and the ﬁltrate was called crude extract.
2.4. Puriﬁcation of L-asparaginase
Crude extract ﬁltrate was precipitated by adding ammonium
sulfate with constant stirring until 80% saturation and incubated
overnight at 5 C to assure that the precipitation had come to
completion. The precipitate was separated by centrifugation at
7722 r/min for 30 min at 5 C. The protein precipitate was
resuspended in 0.01 mol/L Tris–HCl buffer (pH 8.0) and dialyzed
against distilled water. The chromatographic puriﬁcation steps
were performed in a fast protein liquid chromatography (GE
Healthcare, Uppsala, Sweden) with a ﬂow rate of 1 mL/min,
temperature of 20 C and volume fraction of 0.5 mL. The elution
of protein was estimated by measuring the absorbance at 280 nm
(Beckman DU-640, CA, USA). The dialyzed enzyme was ﬁltered
through a 0.45 mm membrane ﬁlter (Millipore, Billerica, MA,
USA) and loaded onto a Q Sepharose™ Fast Flow 1 mL column
(GE Healthcare, Uppsala, Sweden) that was pre-equilibrated with
10mmol/LTris–HCl (pH7.0). The bound enzymewas elutedwith
the NaCl gradient: 0–1.0 mol/L, in the same buffer. Fractions
containing L-asparaginase activity were pooled, dialyzed against
distilled water and concentrated by lyophilization. The lyophi-
lized fraction was resuspended in Tris–HCl buffer (pH 7.0) and
then it was applied to an SP Sepharose™ Fast Flow 1 mL column
(GE Healthcare, Uppsala, Sweden) that was pre-equilibrated with
10 mmol/L Tris–HCl (pH 7.0). The protein elution was done with
the same buffer, and the bound enzyme was eluted with a linear
NaCl gradient: 0–1.0 mol/L. Eluted proteins were pooled,
collected, dialyzed against distilled water and lyophilized. After
resuspension in Tris–HCl buffer (pH 7.0), the enzymewas applied
to the CM Sepharose™ Fast Flow 1 mL column (GE healthcare,
Uppsala, Sweden) previously equilibrated with 10 mmol/L Tris–
HCl (pH7.0). The proteinswere elutedwith a linear NaCl gradient
from 0.0 to 1.0mol/L and collected in 0.5mL fractions. The active
fractions were pooled, dialyzed against distilled water concen-
trated by lyophilization and used for the characterization studies.
2.5. Sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) for puriﬁed L-
asparaginase
The lyophilized L-asparaginase obtained from the CM
Sepharose™ Fast Flow column was subjected to SDS-PAGE to
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the protein. SDS-PAGE was performed on a Mini Protean®
TGX™ precast gel 10% Bio-Rad (Hercules, California, U.S.)
which was employed to achieve separation of proteins [15]. All
gels were run at 200 V for 35 min. Molecular mass markers
(GE Healthcare, Uppsala, Sweden) ranging from 53 to
220 kDa were used, and molecular mass of the puriﬁed
enzyme was determined by plotting the logarithm of protein
molecular mass markers vs. the relative mobility of the
protein. After run time, the gel was directly placed in the
Coomassie brilliant blue R-250 staining solution for 1 h,
destained three times, photographed while wet, dried and kept
for the determination of relative mobility of the puriﬁed L-
asparaginase.
2.6. L-asparaginase and L-glutaminase activity assay
L-asparaginase and L-glutaminase activity of the crude
enzyme solution were assessed by Nesslerization [16]. The
reaction medium was composed of 0.5 mL of 0.04 mol/L L-
asparagine or of 0.04 mol/L L-glutamine, 0.5 mL of 0.1 mol/L
pH 8.0 Tris–HCl buffer, 0.1 mL of enzyme extract and
0.9 mL of distilled water and was incubated at 40 C for
30 min. The reaction was stopped by addition of 0.5 mL of
1.5 mol/L trichloroacetic acid. A 125 mL aliquot of the
reaction mixture was diluted with 1 mL of distilled water, and
125 mL of Nessler's reagent was added to quantify the amount
of ammonia. An analytical curve with ammonium sulfate was
used for the quantiﬁcation of ammonia released (20–450 mmol
ammonia/L). The enzyme activity was expressed in IU/mL of
the substrate, and one unit of enzyme activity (IU) was
deﬁned as the amount of enzyme that liberated 1.0 mmol of
ammonia per minute under standard assay conditions.
2.7. Protein determination
The protein concentration was determined using Lowry
method [17]. A calibration curve at 0.02–20.00 mg/mL
(r2 = 0.9988) was made using bovine serum albumin as
standard.
2.8. Biochemical characterization of L-asparaginase
2.8.1. Effects of pH and temperature on the activity and
stability of L-asparaginase determined using an
experimental design
Univariate studies were previously performed to determine
the central composite design (CCD) levels. The temperature was
investigated over the range from 30 C to 70 C, and the pH was
studied over the range from 3.0 to 10.0.
The optimum pH and temperature for activity and stability
were determined using a CCD with three replicates at the central
point and four axial points (a total of 11 runs). The enzyme was
incubated for 1 h at various pH values (7.0–9.0 for optimum
activity and 6.0–10.0 for stability studies) and temperature
values (40–60 C for optimum activity and 30–70 C for sta-
bility studies) to investigate the L-asparaginase stability. The
experiments were randomized to maximize the variability in the
observed responses caused by exogenous factors. A second-
order model equation was used for this model, represented by
equation (1):Y=b0 +
Xn
i = 1
bixi +
Xn − 1
i = 1
Xn
j = i + 1
bijxiji (1)
where Y is the estimated response, i and j are values from one to
the number of variables (n), b0 is the intercept term. bi values are
the linear coefﬁcients, bij values are the quadratic coefﬁcients,
and xi and xj are the coded independent variables. The coefﬁ-
cient of determination R and the F test (ANOVA) were used to
verify the quality of the ﬁt of the second-order model equation.
The relationships between the responses and the variables were
determined using the Statistica® 7.0 software package from
StatSoft Inc.
2.8.2. Effects of metal ions and inhibitors
The impact of different metal ions and inhibitors on L-
asparaginase activity was investigated at a ﬁnal concentration of
0.05, 0.5 and 5.0 mmol/L, incubating at 25 C for 60 min under
the standard assay conditions. The relative activities were
determined by considering 100% activity of the enzyme in the
absence of additives. Each experiment was performed in
triplicate.
2.8.3. Kinetic parameters
Kinetic parameters were determined using the substrate L-
asparagine (0–3 mmol/L) and L-glutamine (0–40 mmol/L),
separately. The Michaelis–Menten constant (Km) and
maximum velocity (Vmax) were determined as the absolute
reciprocal values of the intercepts on the x and y-axes,
respectively, of the linear regression curve [18]. The
measurements were made at the optimum temperature and pH
as previously determined.
2.9. Antiproliferative activity
2.9.1. Cell lines
Human tumor cell lines [U251 (glioma), UACC-62 (mela-
noma), NCI-ADR/RES (ovary with the multidrug resistance
phenotype), 786-0 (kidney), NCI-H40 (lung, non-small cell
type), PC-3 (prostate), OVCAR-03 (ovarian), HT29 (colon),
K562 (leukemia)] were kindly provided by National Cancer
Institute (Frederick, MA, USA). Non-tumor cell line HaCat
(human keratinocytes) was donated by Prof. Dr. Ricardo Della
Coletta, FOP/UNICAMP. Stock cultures were grown in medium
RPMI 1640 (GIBCO) supplemented with 5% fetal bovine serum
(GIBCO) and 10 IU/mL penicillin, 10 mg/mL streptomycin at
37 C in 5% CO2.
2.9.2. Antiproliferative assay
Cells in 96-well plates (100 mL cells/well) were exposed to L-
asparaginase (isolated from A. oryzae and the commercial one,
ﬁnal concentration 2.0–20.0 IU/mL) at 37 C, 5% of CO2 in air
for 48 h. Doxorubicin was used as standard (0.025, 0.25, 2.5 and
25 mg/mL). Before (T0 plate) and after sample addition (T1
plate), cells were ﬁxed with 50% trichloroacetic acid and cell
growth was determined by spectrophotometric quantiﬁcation
(540 nm) of cellular protein content using sulforhodamine B
assay [19]. The concentration that produces total growth
inhibition (TGI) was determined through non-linear regression
analysis using the concentration–response curve for each cell
line in the software Origin 8.0® (OriginLab Corporation) [20].
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Figure 1. Chromatographic separation of L-asparaginase produced by
A. oryzae CCT 3940.
a: Q Sepharose™ Fast Flow; b: SP Sepharose™ Fast Flow; c: CM
Sepharose™ Fast Flow.
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All values reported in biochemical characterization of the
enzymes represent the mean from three replicates. Signiﬁcant
differences (P < 0.05) between enzymes biochemical properties
were determined by ANOVA. Statistical analyses were per-
formed using the Statistica® 7.0 StatSoft Inc software (Tulsa,
OK, USA).
3. Results
3.1. Puriﬁcation of L-asparaginase and molecular mass
estimation by SDS-PAGE electrophoresis
The L-asparaginase from A. oryzae CCT 3940 was puriﬁed
28.6 folds, with a yield of 6% (Table 1) after sulfate fractionation,
Q Sepharose™ Fast Flow, SP Sepharose™ Fast Flow and CM
Sepharose™ Fast Flow column chromatography (Figure 1). The
puriﬁed L-asparaginase showed a speciﬁc activity of 282 IU/mL
and themolecularmasswas estimated as 115KDa bySDS-PAGE.
3.2. Biochemical characterization of L-asparaginase
3.2.1. Effects of pH and temperature on the activity and
stability of L-asparaginase determined using an
experimental design
The puriﬁed L-asparaginase from A. oryzae CCT 3940
exhibited optimum activity at pH 8.0 and 50 C using univariate
study (Figure 2). Based on these results, the levels of the
experimental design were deﬁned, and the CCD was used to
verify possible interactions between the independent variables.
The highest value obtained for the L-asparaginase activity was in
run 10 (552.2 IU/mL), and the lowest was in run 4 (133.8 IU/
mL) (Table 2). The relative standard deviation (%) of L-aspar-
aginase activity values at the central point of CCD was 13%,
indicating good repeatability for the method developed.
The linear (L) and quadratic (Q) terms for the pH and the
quadratic term for temperature demonstrated a signiﬁcant effect
on L-asparaginase activity, withP-values below0.05 (Table 3).An
ANOVA showed that the model explained 89.12% of the total
variation (Table 4). The F value calculated (8.19) for the regres-
sion was 1.37 folds higher than the F tabulated (3.45), reﬂecting a
statistical signiﬁcance of the model equation (Table 4).
The response surface and the contour plot were generated
from the model (Figure 3a, b). The puriﬁed L-asparaginase from
A. oryzae CCT 3940 was more active in the pH range 7.5–8.0
and the temperature range 45–50 C. The temperature had a
positive effect on L-asparaginase activity. Conversely, the pH
had a negative effect.Table 1
Summary of puriﬁcation procedure of L-asparaginase from A. oryzae CCT 3
Stages of puriﬁcation
process
Volume
(mL)
Enzyme activity
(IU/mL)
Protein
(mg/mL)
Crude extract 1500 60.1 6.10
Ammonium sulfate precipitation 200 175.9 2.70
Q Sepharose™ column 60 182.3 2.00
SP Sepharose™ column 30 209.8 1.80
CM Sepharose™ column 20 276.1 0.98In the experimental design used to determine the pH and
temperature stability for the L-asparaginase from A. oryzae CCT
3940, the highest L-asparaginase activity (539.4 IU/mL) was
achieved in run 7, and the lowest value was 31.6 IU/mL in run 3
(Table 2). The central points (runs 9–11) showed little variation
(relative standard deviation of 18%) indicating good repeat-
ability for the method developed.
For the estimated regression coefﬁcients for the L-aspar-
aginase stability, only the intercept and the linear term of the
temperature showed statistical signiﬁcance with a P
value < 0.05. The pH and temperature linear terms showed
adverse effects on the L-asparaginase stability (Table 3).940.
Total activity
(IU)
Total protein
(mg)
Speciﬁc activity
(IU/mg)
Yield
(%)
Puriﬁcation
factor
90150 9150 10 100 1.0
35180 540 65 39 6.6
10938 120 91 12 9.3
6294 54 117 7 11.8
5522 20 282 6 28.6
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Figure 2. Effects of temperature (a) and pH (b) on the L-asparaginase activity from A. oryzae CCT 3940.
Table 2
CCDmatrix for the determination of the optimum pH and temperature for activity and stability for the L-asparaginase from A. oryzae CCT 3940, with the
coded and real values for the variables and responses.
Run Optimum pH and temperature for activity Optimum pH and temperature for stability
pH* Temperature (C)* L-asparaginase activity (IU/mL) pH* Temperature (C)* L-asparaginase activity (IU/mL)
1 (7.3) −1 (34.4) −1 177.7 (6.6) −1 (36) −1 490.3
2 (8.7) +1 (34.4) −1 164.3 (9.4) +1 (36) −1 528.0
3 (7.3) −1 (55.6) +1 378.1 (6.6) −1 (64) +1 31.6
4 (8.7) +1 (55.6) +1 133.8 (9.4) +1 (64) +1 58.9
5 (7.0) −1.41 (45) 0 368.6 (6.0) −1.41 (50) 0 405.1
6 (9.0) +1.41 (45) 0 167.6 (10.0) +1.41 (50) 0 175.0
7 (8.0) 0 (30) −1.41 227.4 (8.0) 0 (30) −1.41 539.4
8 (8.0) 0 (60) 1.41 443.3 (8.0) 0 (70) 1.41 112.5
9 (8.0) 0 (45) 0 428.0 (8.0) 0 (50) 0 268.0
10 (8.0) 0 (45) 0 552.2 (8.0) 0 (50) 0 310.8
11 (8.0) 0 (45) 0 515.3 (8.0) 0 (50) 0 213.6
*: Real values are in the parenthesis followed by the coded values of the independent variables (pH and temperature) for the determination of the
optimum pH and temperature for the activity and stability of the L-asparaginase from A. oryzae CCT 3940.
Table 3
Estimation of the coefﬁcients obtained from the regression model in the CCD for the optimum pH and temperature for activity and stability for the L-
asparaginase from A. oryzae CCT 3940.
Factors Optimum pH and temperature for activity Optimum pH and temperature for stability
Coefﬁcients Standard error t-value P-value Coefﬁcients Standard error t-value P-value
Intercept 498.84 41.33 12.07 < 0.001 264.27 50.79 5.20 0.003
pH (L) −135.69 50.69 −2.68 0.044 −65.07 62.30 −1.04 0.344
pH (Q) −275.92 60.49 −4.56 0.006 10.34 74.34 0.14 0.895
Temperature (C) (L) 118.94 50.69 2.35 0.066 −383.58 62.30 −6.16 0.002
Temperature (C) (Q) −208.23 60.49 −3.44 0.018 46.44 74.34 0.62 0.560
pH × temperature −115.45 71.58 −1.61 0.168 −5.21 87.97 −0.06 0.955
L: Linear terms; Q: Quadratic terms.
Table 4
ANOVA of a second-order polynomial model for the optimum pH and temperature activity and the stability for L-asparaginase from A. oryzae CCT
3940.
Source of
variation
Optimum pH and temperature for activity Optimum pH and temperature for stability
Sum of
squares
Degrees of
freedom
Mean of
squares
F
test
F
tabulated
Sum of
squares
Degrees of
freedom
Mean of
squares
F
test
F
tabulated
Regression 209882.9 5 41976.6 8.19 3.45 304899.6 5 60979.93 11.9 3.45
Residue 25621.7 5 5124.3 38693.5 5 5124.3
Total 235504.6 10 343593.1 10
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Figure 3. Response surface (a) and contour plots (b) for L-asparaginase optimum activity as a function of pH and temperature.
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the results (Table 4). The value obtained in the F test (11.9) for
the regression was 2.45 folds higher than the critical value,
indicating great signiﬁcance (Table 4).
The response surface and the contour plot of the second-order
polynomial model were generated as a function of the inde-
pendent variables (pH and temperature) (Figure 4a, b). An
evaluation of the contour plot showed that the L-asparaginase
was more stable in the pH range 6.0–7.0 after 1 h incubation at
temperature range 30–40 C, under the assay conditions
(Figure 4). Moreover, the enzyme still showed 112.5 IU/mL
(21% of the highest activity) of activity when incubated at
70 C, at pH 8.0 for 1 h.
3.2.2. Effect of different inhibitors and metal ions on L-
asparaginase activity
The puriﬁed L-asparaginase from A. oryzae CCT 3940 was
not signiﬁcantly affected by the presence of MgSO4 and MnSO4
(0.05 and 0.5 mmol/L). However, at 5 mmol/L those salts acted
as activators for L-asparaginase activity, increasing the activity in
33% and 49%, respectively (Table 5). The presence of NaSO4,
(NH4)2SO4 and NaCl (0.05, 0.5 and 5 mmol/L) did not affect the
puriﬁed L-asparaginase activity; the same occurred in the pres-
ence of CaCl2 (0.05 and 0.5 mmol/L), KCl and CaCO3
(0.05 mmol/L). A slight decrease in L-asparaginase activity was
observed within the presence of FeSO4 (0.05, 0.5 and 5 mmol/
L), CuSO4, KCl, CaCO3 (0.05 and 0.5 mmol/L) and ZnSO40800
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Figure 4. Response surface (a) and contour plots (b) for L-asparaginase stabili(0.05 mmol/L) (Table 5). Moreover, the presence of ZnSO4,
CuSO4 and CaCl2 (5 mmol/L) acted as inhibitors of L-aspar-
aginase activity reducing its activity to around 60%.
A slight decrease, around 30%, on L-asparaginase activity was
observed in the presence of ethylenediaminetetraacetic acid, L-
cysteine, N-bromosuccinimide, iodoacetamide, glutathione and
urea (0.05, 0.5 and 5 mmol/L). The presence of p-chloromercur-
ibenzoate (0.5 and 5mmol/L) acted as a potent inhibitor, reducing
about 53% and 45%, respectively of the L-asparaginase activity.
The presence of sodium azide (0.5 and 5 mmol/L) also acted as an
inhibitor, reducing about 50% of the L-asparaginase activity.
3.2.3. Determination of the kinetic parameters Km and
Vmax
In the enzyme kinetic studies, the puriﬁed L-asparaginase
from A. oryzae CCT 3940 demonstrated high afﬁnity for the
substrate L-asparagine with Km and Vmax values estimated in
0.66 mmol/L and 313 IU/mL, respectively (Figure 5).
Conversely, for the substrate L-glutamine no activity was
detected even when the glutamine concentration was increased
to 40 mmol/L.
3.3. Antiproliferative activity
The cell growth data (%) were expressed in relation to con-
trols cells (T0 and T1), and the doxorubicin proﬁle is shown in
Figure 6a. The assessment of in vitro antiproliferative activity(b)
-1.41              -0.70                  0.00                   0.70                   1.41
pH
ty as a function of the pH and the temperature.
Table 5
The effects of various salts and compounds on the activity of L-aspar-
aginase from A. oryzae CCT 3940.
Ions and inhibitors Residual activity (%)
0.05 mmol/L 0.5 mmol/L 5 mmol/L
MgSO4 99.42 ± 1.78 98.94 ± 1.25 133.64 ± 2.67
MnSO4 103.32 ± 2.06 101.17 ± 3.03 149.58 ± 2.99
CuSO4 87.75 ± 1.44 85.24 ± 2.55 57.50 ± 1.72
NaSO4 99.35 ± 1.78 105.17 ± 3.23 97.36 ± 2.62
ZnSO4 86.25 ± 2.58 58.75 ± 1.76 53.07 ± 1.79
(NH4)2SO4 92.24 ± 1.86 105.16 ± 2.14 99.125 ± 1.17
FeSO4 83.29 ± 1.89 77.13 ± 1.54 77.13 ± 1.54
KCl 98.08 ± 2.64 83.50 ± 1.67 66.04 ± 1.32
NaCl 97.31 ± 1.62 97.24 ± 1.46 95.38 ± 2.58
CaCl2 97.67 ± 1.51 95.48 ± 3.02 46.36 ± 1.21
CaCO3 96.38 ± 1.65 86.22 ± 0.89 80.14 ± 2.31
EDTA 90.54 ± 2.31 93.19 ± 1.78 92.10 ± 3.02
L-cysteine 78.81 ± 3.21 87.58 ± 2.21 85.28 ± 2.33
N-bromosuccinimide 91.24 ± 1.82 88.49 ± 1.92 89.84 ± 1.79
p-
Chloromercuribenzoate
64.73 ± 1.29 46.87 ± 0.79 54.50 ± 1.09
Iodoacetamide 89.34 ± 1.78 86.36 ± 1.29 93.67 ± 2.27
Sodium azide 73.06 ± 2.12 49.02 ± 2.19 49.02 ± 1.89
Urea 82.49 ± 2.47 73.31 ± 1.46 73.32 ± 1.67
Glutathione 92.68 ± 2.23 95.33 ± 1.89 83.26 ± 3.45
Control 100.00 ± 1.20 101.00 ± 0.67 102.00 ± 1.44
EDTA: Ethylenediaminetetraacetic acid. Results are presented as the
mean ± SD (n = 3).
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Figure 5. Lineweaver-Burk plot for L-asparaginase from A. oryzae CCT
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Figure 6. Antiproliferative activity of doxorubicin (a), L-asparaginase from E.
human tumor cells.
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CCT 3940 L-asparaginase and commercial enzyme (Figure 6b,
c). Treatment of different human tumor cell lines with increasing
concentrations of puriﬁed L-asparaginase from A. oryzae CCT
3940 resulted in signiﬁcant cell growth inhibition (Figure 6c).
The sensitivity of the cells lines to puriﬁed L-asparaginase from
A. oryzae CCT 3940 appeared to be concentration dependent
affording a more signiﬁcant decrease in cell growth than that
observed for the commercial L-asparaginase from E. coli
(Table 6). The puriﬁed L-asparaginase from A. oryzae CCT 3940
completely inhibited the cell proliferation of UACC-62 (mela-
noma), 786-0 (kidney), NCI-H40 (lung, non-small cell type),
PC-3 (prostate), NCI-ADR/RES (ovary with the multidrug
resistance phenotype) and K562 (leukemia) cell lines with TGI
values ranging of 3.20–10.00 IU/mL (Table 6). Otherwise,
commercial L-asparaginase only inhibited the growth of UACC-
62 [melanoma, TGI = (7.90 ± 4.00) IU/mL].100
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Table 6
Concentration required to completely inhibit cell proliferation (TGI) for
doxorubicin, commercial L-asparaginase from E. coli and L-asparaginase
from A. oryzae CCT 3940.
Human tumor cell
lines
Commercial L-
asparaginase (IU/
mL)
Puriﬁed L-
asparaginase
(IU/mL)
Doxorubicin
(mg/mL)
U251 (glioma) > 20 > 20 0.05 ± 0.06
UACC-62
(melanoma)
7.90 ± 4.00 5.59 ± 0.06 0.04 ± 0.01
NCI-ADR/RES
(ovary*)
> 20 3.40 ± 4.10 > 25
786-0 (kidney) > 20 5.80 ± 2.40 0.70 ± 0.20
NCI-H40 (lung,
non-small cell
type)
> 20 10.00 ± 1.80 0.20 ± 0.10
PC-3 (prostate) > 20 3.20 ± 4.10 0.55 ± 0.04
OVCAR-03
(ovarian)
> 20 > 20 1.70 ± 0.50
HT29 (colon) > 20 > 20 2.70 ± 1.30
K562 (leukemia) > 20 3.20 ± 2.50 0.31 ± 0.06
HaCat
(immortalized
keratinocytes)
> 20 > 20 0.20 ± 0.20
Results are presented as the mean ± SD (n = 3). *: With the multidrug
resistance phenotype.
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growth of the ovary cell line with resistant phenotype (NCI-ADR/
RES). However, the enzyme from A. oryzae CCT 3940 had
greater efﬁcacy against NCI-ADR/RES cell line with a TGI value
(3.40 ± 4.10) IU/mL. Also, the enzyme from A. oryzae CCT 3940
could inhibit tumor growth of leukemia cell line (K562) with a
TGI value of (3.2 ± 2.5) IU/mL, a value that corresponds to
almost ten times the TGI value for doxorubicin. The doxorubicin
inhibits the proliferation of human keratinocytes cell line (HaCat)
with a small TGI. However, L-asparaginase from A. oryzae CCT
3940 did not inhibit these cell line growths (TGI > 20) at the
concentrations studied. The enzyme puriﬁed from A. oryzae CCT
3940 could inhibit the growth of a broad range of human tumor
cell lines at the concentrations studied.
4. Discussion
4.1. Puriﬁcation of L-asparaginase and molecular mass
estimation by SDS-PAGE
The molecular weight reported in the literature for the L-
asparaginase from Aspergillus terreus (A. terreus) [21] and
A. terreus PC-1.7 [22] was 94 kDa and 136 kDa, and the L-
asparaginase from Penicillium brevicompactum NRC 829
inhibited molecular weight of 94 kDa [23]. Therefore, the value
found in this work (115 kDa) is in accordance with those
reported in the literature. L-asparaginase from A. oryzae CCT
3940 showed only one protein band on SDS-PAGE suggesting
that it contained a single peptide chain.
The L-asparaginase from A. oryzae CCT 3940 presented a
low yield value (6%) probably due to the four-step puriﬁcation.
The speciﬁc activity was higher than those reported for the L-
asparaginase from Mucor hiemalis (M. hiemalis) (69.43 IU/mg)
and for L-asparaginase from Penicillium sp (13.97 IU/mg) [24,25].
4.2. Biochemical characterization of L-asparaginase
L-asparaginase from A. oryzae CCT 3940 presented a higher
optimum temperature and an intermediary optimum pH when
compared with the values reported for L-asparaginase from
A. terreus (25 C, pH 6.0) [21] and for L-asparaginase from
Aspergillus niger AK-10 (35 C, pH 9.0) [26]. Also, the L-
asparaginase from A. oryzae CCT 3940 showed high stability
in the range from 30 to 45 C and pH range 7.0–8.0 after 1 h
of incubation meaning that the enzyme is stable under
physiological conditions, which can be useful for further
medical applications. Moreover, the enzyme still showed
112.5 IU/mL of activity (21% of the highest activity) when
incubated at 70 C and pH 8.0, indicating high thermal stability.
The Mn2+ (2 mmol/L) acted as an activator for L-asparaginase
from M. hiemalis and Rhizomucor miehei [24,27]. An increase in
the L-asparaginase activity was also observed for the L-
asparaginase from A. oryzae CCT 3940 in the presence of
Mn2+ (5 mmol/L). In this study, the L-asparaginase was
strongly inhibited (50% of reduction) in the presence of p-
chloromercuribenzoate and also inhibited (30% of reduction)
in the presence of iodoacetamide (0.5 and 5 mmol/L).
Inhibition in the presence of thiol group blocking reagents
provided an indication of the presence of sulfhydryl groups in
the catalytic activity of the enzyme [28].The Km value (0.66 mmol/L) found for the puriﬁed L-
asparaginase from A. oryzae CCT 3940 was lower than those
reported for L-asparaginase from M. hiemalis (4.3 mmol/L) [24],
for L-asparaginase from A. terreus (2.42 mmol/L) [22] and for L-
asparaginase from Penicillium brevicompactum NRC 829
(1.05 mmol/L) [23]. The data indicated that the enzyme
extracted from A. oryzae CCT 3940 is very speciﬁc to its
natural substrate L-asparagine. Also, L-asparaginase from
A. oryzae CCT 3940 exhibited no glutaminase activity even in
an elevated concentration of glutamine. L-asparaginase
preparations that do not show glutaminase activity have an
excellent potential for medical applications [29].
4.3. Antiproliferative activity
The enzyme puriﬁed from A. oryzae CCT 3940 could inhibit
the growth of a broad range of human tumor cell lines at the
concentrations studied.
Gui et al. reported that commercial L-asparaginase from
bacteria was effective in the treatment of primary lung lym-
phoma (NKT line) [30]. Shanmugaprakash et al. assessed the
antiproliferative effect of L-asparaginase puriﬁed from pepper
(Capsicum annuum L.) against three human tumor cell lines
HeLa (cervical adenocarcinoma), A549 (lung) and KB (oral
cell carcinoma) using a cell viability assay and concluded that
treatment with L-asparaginase decreases the viability of all
three tumor lines signiﬁcantly with a dose-dependent response
[31]. Lorenzi et al. studied the correlation of production of L-
asparagine synthetase with the L-asparaginase activity and they
reported that the human tumor cell lines OVACAR-03 (ovary)
and NCI/ADR (ovary with resistant phenotype) required con-
centrations of 0.86 IU/mL and 0.20 IU/mL, respectively, for
inhibiting the growth by 50% [32]. The enzyme puriﬁed from
A. oryzae CCT 3940 reported here could completely inhibit
the growth of human tumor cell line NCI/ADR (resistant
phenotype with ovary) at a concentration of 3.5 IU/mL.
In conclusion, the puriﬁed glutaminase-free-L-asparaginase
from A. oryzae CCT 3940 presented a molecular mass estimated
in 115 kDa. L-asparaginase showed optimum activity in the pH
range 7.0–8.0 and temperature range 40–50 C. L-asparaginase
showed high stability under physiological condition, remaining
stable in the pH range 7.0–8.0 after 1 h incubation at temperature
range 30–45 C. The enzyme showed high afﬁnity to L-aspara-
gine with Km and Vmax values of 0.66 mmol/L and 313 IU/mL,
respectively. The L-asparaginase was activated by the presence
of MgSO4 and MnSO4, at a concentration of 5 mmol/L. Treat-
ment of different human tumor cell lines with increasing con-
centrations of puriﬁed L-asparaginase from A. oryzae CCT 3940
results in signiﬁcant cell growth inhibition. The puriﬁed L-
asparaginase showed greater antiproliferative activity than the
commercial enzyme, completely inhibiting the growth of
UACC-62 (melanoma), NCI-ADR/RES (ovary with the multi-
drug resistance phenotype), 786-0 (kidney), NCI-H40 (lung,
non-small cell type), PC-3 (prostate) and K562 (leukemia) cell
lines. The cytostatic antibiotic doxorubicin could not inhibit cell
growth of the ovary with the multidrug resistance phenotype
(NCI-ADR/RES). The enzyme from A. oryzae CCT 3940 had
greater efﬁcacy with a TGI value of 3.5 IU/mL. Also, the
enzyme from A. oryzae CCT 3940 could inhibit tumor growth of
leukemia cell line (K562) with a TGI value of (3.2 ± 2.5) IU/mL.
Fernanda Furlan Gonçalves Dias et al./Asian Pac J Trop Biomed 2016; 6(9): 785–794 793The doxorubicin inhibits the proliferation of human keratino-
cytes cell line (HaCat) with a small TGI. However, L-aspar-
aginase from A. oryzae CCT 3940 did not inhibit these cell line
growths (TGI > 20) at the concentrations studied. The anti-
proliferative effect of the enzyme seems to be dose-dependent.
Therefore, the new puriﬁed L-asparaginase from A. oryzae
CCT 3940 has high value for future application in the clinical
investigation. The production of the free-glutaminase L-aspar-
aginase stable at physiological temperature suggests that this
enzyme could be used in the formulations for the therapy of
acute lymphoblastic leukemia and could be less susceptible to
cause side effects, which makes it advantageous for future
clinical investigation.
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